Atreca, Inc., a Redwood City, Calif.-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, completed a $35M Series B financing.
The round was co-led by Wellington Management Company and by a large US-based, healthcare-focused fund, with participation from Cormorant Asset Management, as well as other investors.
The company intends to use the funds to accelerate and broaden its discovery and development of antibody-based therapeutics for cancer patients.
Led by Tito A. Serafini, Ph.D., President, Chief Executive Officer, and Co-Founder, and Brian Atwood, Chairman, Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. The company’s proprietary Immune Repertoire Capture® technology is able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes.